Maxim Group Reiterates Buy Rating for Juno Therapeutics, Inc. (JUNO)

Juno Therapeutics, Inc. (NASDAQ:JUNO)‘s stock had its “buy” rating reissued by stock analysts at Maxim Group in a research note issued on Thursday. They currently have a $56.00 price target on the biopharmaceutical company’s stock. Maxim Group’s price objective points to a potential downside of 4.24% from the company’s previous close.

JUNO has been the topic of several other research reports. Zacks Investment Research lowered shares of Juno Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, August 3rd. Morgan Stanley boosted their price target on shares of Juno Therapeutics from $26.00 to $27.00 and gave the company an “equal weight” rating in a report on Monday, August 7th. Vetr lowered shares of Juno Therapeutics from a “hold” rating to a “sell” rating and set a $28.47 price target on the stock. in a report on Monday, August 7th. Cowen and Company reaffirmed a “buy” rating and issued a $49.00 target price on shares of Juno Therapeutics in a report on Friday, October 27th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $64.00 target price (up previously from $42.00) on shares of Juno Therapeutics in a report on Thursday. Three equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and nine have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $44.20.

Shares of Juno Therapeutics (NASDAQ:JUNO) traded down $1.43 during trading on Thursday, reaching $58.48. 5,482,719 shares of the company’s stock traded hands, compared to its average volume of 2,209,417. The company has a debt-to-equity ratio of 0.01, a quick ratio of 5.08 and a current ratio of 4.77. Juno Therapeutics has a 12-month low of $17.52 and a 12-month high of $61.59.

Juno Therapeutics (NASDAQ:JUNO) last announced its quarterly earnings results on Wednesday, November 1st. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.80) by $0.07. The firm had revenue of $44.80 million for the quarter, compared to analyst estimates of $18.12 million. Juno Therapeutics had a negative net margin of 332.05% and a negative return on equity of 32.54%. The business’s revenue for the quarter was up 115.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.57) EPS. analysts expect that Juno Therapeutics will post -3.62 EPS for the current fiscal year.

COPYRIGHT VIOLATION WARNING: This news story was reported by Community Financial News and is the sole property of of Community Financial News. If you are accessing this news story on another domain, it was illegally stolen and republished in violation of international copyright laws. The legal version of this news story can be read at https://www.com-unik.info/2017/11/05/maxim-group-reiterates-buy-rating-for-juno-therapeutics-inc-juno.html.

In related news, EVP Robert Azelby sold 12,869 shares of the company’s stock in a transaction dated Tuesday, August 29th. The shares were sold at an average price of $39.95, for a total transaction of $514,116.55. Following the transaction, the executive vice president now owns 50,289 shares in the company, valued at approximately $2,009,045.55. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Richard Klausner sold 12,000 shares of the company’s stock in a transaction dated Monday, August 7th. The stock was sold at an average price of $30.34, for a total transaction of $364,080.00. Following the transaction, the director now owns 788,985 shares in the company, valued at approximately $23,937,804.90. The disclosure for this sale can be found here. In the last quarter, insiders have sold 91,670 shares of company stock worth $3,917,857. 15.26% of the stock is owned by corporate insiders.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Utah Retirement Systems lifted its position in Juno Therapeutics by 1.8% during the 2nd quarter. Utah Retirement Systems now owns 11,600 shares of the biopharmaceutical company’s stock worth $347,000 after buying an additional 200 shares in the last quarter. State of Wisconsin Investment Board lifted its position in Juno Therapeutics by 1.7% during the 2nd quarter. State of Wisconsin Investment Board now owns 12,562 shares of the biopharmaceutical company’s stock valued at $375,000 after purchasing an additional 210 shares during the period. The Manufacturers Life Insurance Company lifted its position in Juno Therapeutics by 7.2% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 3,405 shares of the biopharmaceutical company’s stock valued at $102,000 after purchasing an additional 228 shares during the period. Aperio Group LLC lifted its position in Juno Therapeutics by 4.2% during the 3rd quarter. Aperio Group LLC now owns 29,554 shares of the biopharmaceutical company’s stock valued at $1,326,000 after purchasing an additional 1,194 shares during the period. Finally, Amalgamated Bank lifted its position in Juno Therapeutics by 19.0% during the 2nd quarter. Amalgamated Bank now owns 10,900 shares of the biopharmaceutical company’s stock valued at $326,000 after purchasing an additional 1,741 shares during the period. Institutional investors and hedge funds own 67.18% of the company’s stock.

Juno Therapeutics Company Profile

Juno Therapeutics, Inc (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells.

Analyst Recommendations for Juno Therapeutics (NASDAQ:JUNO)

What are top analysts saying about Juno Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Juno Therapeutics Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit